Preferred Label : Anti-c-Met Antibody-drug Conjugate YL211;
NCIt synonyms : Anti-c-Met/TOP1i ADC YL211; Anti-c-Met/TOP1i Antibody-drug Conjugate YL211; Anti-c-Met ADC YL211;
NCIt definition : An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed
against the tumor-associated antigen (TAA) proto-oncogene c-Met (hepatocyte growth
factor receptor; HGFR) site-specifically conjugated, via a tumor microenvironment
(TME) activable protease-cleavable linker, to a topoisomerase 1 inhibitor (TOP1i),
with potential antineoplastic activity. Upon administration of anti-c-Met ADC YL211,
the anti-c-Met antibody moiety targets and binds to c-Met expressed on tumor cells.
Upon proteolytic cleavage in the TME and the release of the topoisomerase I inhibitor,
the topoisomerase I inhibitor targets and binds to DNA topoisomerase I, thereby inhibiting
DNA replication and killing the c-Met-expressing cancer cells. In addition, YL211
is able to induce a bystander effect on neighboring cells. This further inhibits tumor
cell proliferation. c-Met, a receptor tyrosine kinase overexpressed or mutated in
many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion,
metastasis and tumor angiogenesis.;
Molecule name : YL 211; YL-211;
Origin ID : C209974;
concept_is_in_subset
- has_target
